GANX Company Profile and Key Details

Gain Therapeutics, Inc. has 35.95 million shares outstanding. The public float is 29.58 million shares, elevated short interest at 0.73% of float. This equals 243.00 thousand shares. The short ratio is 0.82 days. Institutional investors hold 10.96% of the float. Insiders own 3.64%. RICHMAN ERIC I holds 277.63 thousand shares, Islam Khalid has 50.00 thousand shares and Riley Jeffrey Scott has 30.00 thousand shares.

Short-term trend indicators are mixed aligned (SMA20 -10.42%, SMA50 -36.9%, SMA200 -16.65%). The stock’s 14-day RSI is 36.87 (weak momentum), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -59.68% below its high and over 24.11% above its low. Average 10-day trading volume of 550.92 thousand shares is below the 3-month average of 1.36 million, indicating normal recent market interest.

Gain Therapeutics, Inc. generated EPS of -$0.64 over the past year. Five-year average earnings growth is -37.02%. Wall Street analysts project EPS growth of 2.3% annually over the next five years. The latest quarter delivered EPS of -$0.15. The next quarter is forecast at -$0.14. Next year's EPS is expected at $23.12. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $6.00. The high target offers 585.71% upside. The low target suggests 242.86% downside. The mean target is $8.10. This offers 362.86% upside. Gain Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 0.66%. The prior quarter beat by 11.76%. Over the last six quarters, Apple has recorded several small beats. These include 36.7% in August 08, 2024.

Gain Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.43. This means the shares are trading above this model’s fair value.

Gain Therapeutics, Inc. trades at a P/E ratio of -3.23, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 10.6 reflecting a rich premium to book value. The P/FCF stands at -3.98, also above market averages. Compared to sector medians, Gain Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Gain Therapeutics, Inc. (NASDAQ:GANX) closed at $1.75 USD, gaining $0.13 (8.02%) from the previous close of $1.62. The stock is currently mid-range between its 52-week high and low $1.41 and $4.34. With a market capitalization of about $67.31 million, Gain Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.06). Key stats such as the average daily volume over the past year has been around 1.50 million shares, volume is running light vs its 52-week average. Headquartered in Bethesda, MD, Gain Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gene Mack, the company employs approximately 23 people and listed since March 19, 2021. Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding.

Our AI price prediction model suggests that Gain Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -30.29%, with price expected at $1.22 by February 20, 2026, within a range of $0.94 to $1.47 3-Month Outlook: Projected rise of 149.71%, reaching $4.37 by May 06, 2026, with a range of $4.30 to $4.46. 1-Year Outlook: Projected gain of 488.57%, with price at $10.30 by February 05, 2027, within a range of $2.23 to $16.36.

Gain Therapeutics, Inc. (NASDAQ:GANX) shares are down -38.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Gain Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.23. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.80, suggesting 402.86% upside. Our AI forecast model points to short-term weakness (-30.29% over two weeks), a medium-term rise (149.71% over three months), and a longer-term gain (488.57% over one year), with expected trading ranges indicating moderate volatility.